The Phase 3 SYNERGY-Outcomes entry covering adults with metabolic dysfunction-associated steatotic liver disease was updated on 8 October 2026.
Bethesda, Maryland, 8 October 2026 — The ClinicalTrials.gov registry record with identifier NCT07165028, a Phase 3 interventional study sponsored by Eli Lilly and Company, was last updated on 8 October 2026 and carries the overall status recruiting. The registered brief title describes a master protocol covering multiple agents in adults with metabolic dysfunction-associated steatotic liver disease.
Source documents
-
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Identifier
- Registry identifier NCT07165028
- Registry status
- RECRUITING
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Last update posted
- 2026-10-08